NCT02511522View on ClinicalTrials.gov

Study of Palliative Radiotherapy for Symptomatic Hepatocellular Carcinoma and Liver Metastases

NACompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

December 11, 2015

Primary Completion Date

October 26, 2022

Study Completion Date

October 2, 2024

Conditions
Hepatocellular CarcinomaLiver Metastases
Interventions
OTHER

Best Supportive Care

Including analgesics, palliative care and/or pain specialist assessment as needed

RADIATION

Palliative Radiation Therapy

8 Gy in 1 fraction in whole liver or near whole liver. Including anti-emetic pre-medications

Trial Locations (7)

A1B 3V6

Dr. H. Bliss Murphy Cancer Centre, St. John's

L4M 6M2

Royal Victoria Regional Health Centre, Barrie

K7L 2V7

Kingston Health Sciences Centre, Kingston

K1H 8L6

Ottawa Hospital Research Institute, Ottawa

M5G 2M9

University Health Network, Toronto

H2X 3E4

CHUM-Centre Hospitalier de l'Universite de Montreal, Montreal

G8Z 3R9

Centre hospitalier regional de Trois-Rivieres, Trois-Rivières

All Listed Sponsors
lead

Canadian Cancer Trials Group

NETWORK

NCT02511522 - Study of Palliative Radiotherapy for Symptomatic Hepatocellular Carcinoma and Liver Metastases | Biotech Hunter | Biotech Hunter